For example, FOXN1's role in immune regulation raises the possibility that its expression may enhance the tumor's immunogenicity, making patients more responsive to immune checkpoint inhibitors, which have become a key therapy for LUSC. This evidence concerns the gene FOXN1 and neoplasm.